Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02293265 | Cross-sectional Study for Identification and Description of Severe Asthma Patients | PHASE3 | COMPLETED | 767 | — | — | Dec 1, 2014 | May 1, 2015 | Apr 4, 2016 | 74 | United States, Australia +4 |
Biologic treatments for asthma will include mepolizumab (anti-Interleukin \[IL\] 5), omalizumab (anti-immunoglobulin E \[IgE\]), and reslizumab (anti-IL5).
| Arm | Type | Description |
|---|---|---|
| Non-drug interventional group | OTHER | All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants. |
| Name | Type | Description |
|---|---|---|
| Short Acting Beta Agonist (SABA) | DRUG | Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments |
Inclusion Criteria: * At least 12 years of age at study visit. * Participants eligible for enrolment and entry into the study must meet the following definition of severe asthma, which is based on the definition of severe asthma described in the European Respiratory Society/ American Thoracic Socie...